Breast cancer has become the most common cancer in the US and worldwide. While
advances in early detection and treatment have resulted in a 40% reduction in breast cancer …

Baseline cardiovascular assessment before the initiation of potentially cardiotoxic cancer
therapies is a key component of cardio-oncology, aiming to reduce cardiovascular …

Modern cancer therapies greatly improve clinical outcomes for both early and advanced
breast cancer patients. However, these advances have raised concerns about potential …

Every year, more than a million people in the United States undergo chemotherapy or
radiation therapy for cancer, as estimated by the CDC. While chemotherapy has been an …

Abstract Background and Aims Baseline cardiovascular toxicity risk stratification is critical in
cardio-oncology. The Heart Failure Association (HFA) and International Cardio-Oncology …

Breast cancer chemotherapy/immunotherapy can be associated with treatment-limiting
cardiotoxicity. Radiomics techniques applied to ultrasound, known as ultrasomics, can be …

Background: Risk stratification strategies for cancer therapeutics-related cardiac dysfunction
(CTRCD) rely on serial monitoring by specialized imaging, limiting their scalability …

Survivorship issues and treatment related toxicities have considerably increased in breast
cancer patients following improved therapeutic options. Cardiotoxicity has been a major …

TOP2 inhibitors (TOP2i) are effective drugs for breast cancer treatment. However, they can
cause cardiotoxicity in some women. The most widely used TOP2i include anthracyclines …

Doxorubicin (DOX), a commonly used anticancer agent, causes cardiotoxicity that begins
with the first dose and may progress to heart failure years after treatment. An inflammatory …